Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2017-06-01
Serija:	Blood Advances
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
Oznake:	Označite Brez oznak, prvi označite!